Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Return on Capital Employed (2020 - 2026)

ADC Therapeutics has reported Return on Capital Employed over the past 7 years, most recently at 53.75% for Q1 2026.

  • Quarterly results put Return on Capital Employed at 53.75% for Q1 2026, down 84.0% from a year ago — trailing twelve months through Mar 2026 was 53.75% (down 84.0% YoY), and the annual figure for FY2022 was 0.08%, up 4249790.0%.
  • Return on Capital Employed reached 53.75% in Q1 2026 per ADCT's latest filing, up from 57.12% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 1080.4% in Q1 2024 and bottomed at 14341.72% in Q3 2022.
  • Median Return on Capital Employed over the past 5 years was 983.88% (2023), compared with a mean of 3484.5%.
  • The largest annual shift saw Return on Capital Employed skyrocketed 1243298bps in 2023 before it plummeted -113330bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 2642.44% in 2022, then grew by 28bps to 1908.73% in 2023, then surged by 98bps to 45.9% in 2024, then dropped by -24bps to 57.12% in 2025, then rose by 6bps to 53.75% in 2026.
  • Business Quant data shows Return on Capital Employed for ADCT at 53.75% in Q1 2026, 57.12% in Q3 2025, and 59.03% in Q2 2025.